Carl June, M.D.
Carl June, M.D. is Professor, Director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania, and is an Investigator of the Abramson Family Cancer Research Institute. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-1979 and post-doctoral training in transplantation biology with Dr. E. Donnell Thomas at the Fred Hutchinson Cancer Research Center in Seattle from 1983 - 1986. He is board certified in Internal Medicine and Medical Oncology. He founded the Immune Cell Biology Program and was head of the Department of Immunology at the Naval Medical Research Institute from 1990 to 1995. He rose to Professor in the Departments of Medicine and Cell and Molecular Biology at the Uniformed Services University for the Health Sciences in Bethesda, Maryland before assuming his current position as of February 1, 1999. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy. He is the scientific founder of Xcyte Therapies, Inc. and Tmune Therapeutics, Inc.
Randy Noelle, Ph.D.
Randy Noelle, Ph.D. is Professor and Chair of Microbiology and Immunology, Dartmouth Medical School and Director of the Immunotherapy Center, as well as co-director of the Norris Cotton Cancer Center's Immunology and Cancer Immunotherapy Research Program. He was a post-doctoral fellow at the University of Texas Health Science Center at Dallas from 1980-1984 and, in 1984, he joined the faculty of Dartmouth Medical School as an Assistant Professor. In 1995, he was promoted to Professor of Microbiology. His laboratory has identified a novel membrane protein expressed on helper T lymphocytes (Th), CD154 and studies the regulation of peripheral tolerance.
Michel Nussenzweig, M.D., Ph.D.
Michel Nussenzweig, M.D., Ph.D. is Professor of Molecular Immunology, Howard Hughes Medical Institute (HHMI), Rockefeller University. Dr. Nussenzweig is also Sherman Fairchild Professor and Senior Physician at Rockefeller. He obtained his Ph.D. degree for work on dendritic cells with Ralph Steinman at Rockefeller. He earned an M.D. degree from New York University Medical School. Dr. Nussenzweig trained in internal medicine and infectious diseases at Massachusetts General Hospital, Boston. His postdoctoral research was done with Philip Leder at Harvard Medical School on immunoglobulin genes and B cell development.
Jeffrey S. Weber, M.D., Ph.D.
Jeffrey S. Weber, M.D., Ph.D. is Deputy Director of the Laura and Isaac Perlmutter Cancer Center and Professor of Medicine at NYU Langone Medical Center, Co-director of its Melanoma Program and its Head of Experimental Therapeutics. Dr. Weber was previously Director of the Donald A. Adam Comprehensive Research Center and Senior Member at Moffitt Cancer Center. He was also Professor and Associate Chair in the Department of Oncologic Sciences at the University of South Florida. Dr. Weber has been a clinical trialist and translational investigator for over 25 years and is an expert in cancer immunotherapy and melanoma research. Dr. Weber’s areas of interest include the use of vaccines and biologic compounds to treat melanoma, specifically antibodies against immune regulatory molecules and cytokine vaccine adjuvants. Recent clinical trials for which he is the principal investigator have included the use of multi-peptide vaccines with PD-1 antibody for patients with metastatic and resected melanoma, PD-1 antibody with CTLA-4 antibody and selective HDAC inhibition for patients with metastatic melanoma, and the use of TRAIL-R2 agonistic agents to augment apoptosis and deplete myeloid derived suppressor cells in stage IV melanoma. Dr. Weber received his M.D. from New York University and his Ph.D. from the Rockefeller University, and he completed a fellowship in medical oncology at the National Cancer Institute.
Louis Weiner, M.D.
Louis Weiner, M.D. is Director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, where he is the Francis L. and Charlotte G. Gragnani Chair and Professor, and Chairman of the Department of Oncology. He also serves as Director of Cancer Services at Georgetown University Hospital. He was previously Chairman of Medical Oncology and Vice President for Translational Research at the Fox Chase Cancer Center. A medical oncologist trained in research, Dr. Weiner developed and directed the medical oncology fellowship program before becoming department chairman at Fox Chase. He specializes in treating patients with cancers of the gastrointestinal system. Dr. Weiner’s laboratory and clinical research focus on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies. He has organized numerous international meetings on antibody engineering and immunotherapy, published more than 150 scientific papers, and lectures extensively on targeted therapies for cancer. Dr. Weiner earned his BA with honors in biology at the University of Pennsylvania and his MD at Mount Sinai School of Medicine of New York University in New York City. After completing his internship, residency, and chief medical residency at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston. Dr Weiner is board certified in internal medicine and medical oncology by the American Board of Internal Medicine.